XtalPi Platform
Accelerating R&D with AI, quantum physics, and robotics for molecular discovery.
Executive Summary
XtalPi Platform, also known as the Intelligent Digital Drug Discovery and Development (ID4) platform, leverages artificial intelligence, quantum physics, cloud computing, and robotics to accelerate drug discovery and development, and material science research. It is primarily used by pharmaceutical companies, biotechnology firms, and research institutions to enhance their R&D pipelines, reduce development costs, and shorten time-to-market for new molecules. Its key differentiation lies in the deep integration of computational power with automated experimental labs, creating an intelligent closed-loop system for data-driven innovation.
Use Cases
- Accelerating small molecule drug discovery from hit identification to lead optimization.
- Optimizing solid-state forms of drug candidates, including polymorph and salt screening.
- Designing and optimizing novel materials for various industries like renewable energy and new chemicals.
- Automating and digitizing laboratory experimental processes for enhanced efficiency and data quality.
- Predicting and optimizing key properties of molecules such as efficacy, selectivity, and developability.
- Target identification and validation for novel therapies, particularly in oncology.
Features
Visibility
- Digitization of Laboratory Data: Processes and analyzes laboratory data more accurately and reliably, facilitating discovery and resolution of experimental challenges.
- Real-time Experimental Monitoring: Automated systems operate 24/7 to execute experiments and record data, providing continuous monitoring and insights.
- Integrated R&D Workflow Visualization: Provides a comprehensive view of the drug discovery journey from target identification to preclinical candidates.
Intelligence
- AI Generative Molecular Designs: Enables exploration of ultra-large chemical spaces and generation of diverse novel compounds for various molecular design scenarios.
- High-Throughput Virtual Screening: Efficiently screens ultra-large chemical libraries, enhanced by active learning to identify promising molecules.
- Accurate Binding Affinity Predictions (XFEP): Physics-based free energy perturbation technology predicts protein-ligand binding with experimental-matching accuracy across various drug design scenarios.
- Crystal Structure Prediction (XtalCSP): Predicts thermodynamically stable crystal forms, including polymorphs, solvates, and co-crystals, to de-risk solid-state research.
- AI-Powered Chemistry Algorithms: Analyzes target molecules for reaction viability, removing those with low synthetic success probability and optimizing chemical synthesis.
Support
- Expert Consultation & Collaboration: Partnership model allows leveraging XtalPi's expertise and technological capabilities for co-development and discovery projects.
- Dedicated Account Management: Implied through long-term commercial agreements and strategic collaborations with pharmaceutical companies.
- Technical Documentation & Training: Supports users in effectively utilizing the platform's advanced computational and experimental tools.
Technical Specifications
- Architecture
- Cloud-native SaaS with integrated intelligent experimental closed-loop system and automated laboratories.
- Deployment
- Hybrid
- Authentication
- Not specified
- API Available
- Yes
- MCP Server
- No
Infrastructure
- AWS
- GCP
AI/ML Stack
- Machine Learning
- Deep Learning
- Graph Neural Networks
- Transformers
- Generative AI
- Quantum Algorithms
- LLM
Integrations
- Quantum Computing
- Laboratory Automation
Security & Compliance
Encryption: Default encryption for multi-cloud architecture.
Pricing
- Model
- Subscription basis, milestone payments, royalty payments, custom enterprise
- Starting Price
- Contact sales
- Target Customer
- Mid-market to Enterprise
- Contract Type
- Annual, Multi-year discounts
- Free Trial
- Yes, Custom demo (credit card required)
About XtalPi
XtalPi is a publicly listed biotechnology company that leverages AI, quantum physics, and robotics to accelerate drug discovery and materials research. They provide integrated solutions to streamline R&D processes, reducing time and waste in developing new therapies.